UNSPSC 51361931: Brallobarbital calcium

This classification denotes a barbiturate 2C10H10BrN2O3.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L214YQB674, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-bromo-2-propenyl)-5-(2-propenyl)-, calcium salt (2:1), but more generally known as brallobarbital calcium, which bears US NIH Compound Identifier 71301214. European Medicines Agency schedules Brallobarbital calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00865MIG.

Most nations, for tariff and trade purposes, schedule brallobarbital calcium under HS 29335400 and SITC kg. As of Q4 2014, BRALLOBARBITAL CALCIUM remains US FDA's Preferred Term for this commodity. SMILES: C=CCC1(C(=O)NC(=O)[N-]C1=O)CC(=C)BR.C=CCC1(C(=O)NC(=O)[N-]C1=O)CC(=C)BR.[CA+2].

UNSPSC 51361931 Brallobarbital calcium is a Commodity code, but recent state and local procurement activity under this code shows minimal direct relevance. The three most recent opportunities posted involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations specifically target brallobarbital calcium or barbiturate-class pharmaceuticals; the code appears to see limited activity or has been applied to broader pharmaceutical procurement categories that do not align with its narrow commodity definition.

The issuing bodies span county health departments, state health agencies, and multistate cooperative purchasing vehicles. Geographic activity is concentrated in Florida, Texas, and Minnesota based on recent postings. The Seminole County opportunity (IFB60459723LAS, due July 26, 2023) is a traditional competitive bid for annual supply of naloxone and drug deactivation systems with quarterly deliveries. The Texas HHS Request for Information (RFI HHS0017013, April 2026) is exploratory market research into direct-to-manufacturer prescription programs. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) establishes multistate contracts for generic pharmaceuticals and OTC products through authorized wholesalers. Given the disconnect between the code's stated scope and what is actually being solicited, this code warrants close attention to verify its applicability to your target product lines before pursuing opportunities tagged under it.